Rallybio Corp Stock Performance
| RLYB Stock | USD 0.33 0.01 4.19% |
The company holds a Beta of 1.49, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rallybio Corp will likely underperform. At this point, Rallybio Corp has a negative expected return of -0.13%. Please make sure to check Rallybio Corp's skewness, as well as the relationship between the day median price and relative strength index , to decide if Rallybio Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Rallybio Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks | 04/09/2025 |
2 | This General Motors Analyst Is No Longer Bullish Here Are Top 5 Downgrades For Tuesday | 04/15/2025 |
3 | Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria | 04/23/2025 |
4 | Acquisition by Martin MacKay of 436517 shares of Rallybio Corp subject to Rule 16b-3 | 04/25/2025 |
5 | Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates | 05/08/2025 |
6 | Acquisition by Martin MacKay of 28500 shares of Rallybio Corp at 0.3 subject to Rule 16b-3 | 05/13/2025 |
7 | Acquisition by Hopfner Robert Lorne of 28500 shares of Rallybio Corp at 0.3 subject to Rule 16b-3 | 05/15/2025 |
8 | Rallybios SWOT analysis C5 inhibitor focus shifts stock outlook - Investing.com | 05/22/2025 |
9 | Acquisition by Hunt Ronald of 13440 shares of Rallybio Corp at 12.75 subject to Rule 16b-3 | 05/28/2025 |
10 | Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory PharmacokineticPharmacodynamic Study | 06/12/2025 |
11 | Rallybio Finalizes Employment Agreement with CMO - TipRanks | 06/27/2025 |
| Begin Period Cash Flow | 24.5 M |
Rallybio Corp Relative Risk vs. Return Landscape
If you would invest 45.00 in Rallybio Corp on April 4, 2025 and sell it today you would lose (13.00) from holding Rallybio Corp or give up 28.89% of portfolio value over 90 days. Rallybio Corp is currently does not generate positive expected returns and assumes 8.8039% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Rallybio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rallybio Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rallybio Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rallybio Corp, and traders can use it to determine the average amount a Rallybio Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0153
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RLYB |
Estimated Market Risk
| 8.8 actual daily | 78 78% of assets are less volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rallybio Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rallybio Corp by adding Rallybio Corp to a well-diversified portfolio.
Rallybio Corp Fundamentals Growth
Rallybio Stock prices reflect investors' perceptions of the future prospects and financial health of Rallybio Corp, and Rallybio Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rallybio Stock performance.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (45.61) % | ||||
| Current Valuation | (40.94 M) | ||||
| Shares Outstanding | 41.61 M | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 15.85 X | ||||
| Revenue | 636 K | ||||
| Gross Profit | (38.66 M) | ||||
| EBITDA | (60.5 M) | ||||
| Net Income | (57.77 M) | ||||
| Cash And Equivalents | 147.37 M | ||||
| Cash Per Share | 4.59 X | ||||
| Total Debt | 154 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (49.28 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Total Asset | 68.11 M | ||||
| Retained Earnings | (293.02 M) | ||||
About Rallybio Corp Performance
By analyzing Rallybio Corp's fundamental ratios, stakeholders can gain valuable insights into Rallybio Corp's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Rallybio Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rallybio Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporaton operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.Things to note about Rallybio Corp performance evaluation
Checking the ongoing alerts about Rallybio Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rallybio Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rallybio Corp generated a negative expected return over the last 90 days | |
| Rallybio Corp has high historical volatility and very poor performance | |
| Rallybio Corp has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 636 K. Net Loss for the year was (57.77 M) with loss before overhead, payroll, taxes, and interest of (38.66 M). | |
| Rallybio Corp currently holds about 147.37 M in cash with (49.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Rallybio Finalizes Employment Agreement with CMO - TipRanks |
- Analyzing Rallybio Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rallybio Corp's stock is overvalued or undervalued compared to its peers.
- Examining Rallybio Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rallybio Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rallybio Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rallybio Corp's stock. These opinions can provide insight into Rallybio Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Rallybio Stock analysis
When running Rallybio Corp's price analysis, check to measure Rallybio Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rallybio Corp is operating at the current time. Most of Rallybio Corp's value examination focuses on studying past and present price action to predict the probability of Rallybio Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rallybio Corp's price. Additionally, you may evaluate how the addition of Rallybio Corp to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |